Sanofi Adr Stock Performance
| SNY Stock | USD 45.39 0.72 1.56% |
The entity has a beta of 0.14, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sanofi ADR's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sanofi ADR is expected to be smaller as well. Sanofi ADR has an expected return of -0.17%. Please make sure to validate Sanofi ADR treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Sanofi ADR performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sanofi ADR has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.56) | Five Day Return (1.28) | Year To Date Return (9.22) | Ten Year Return (13.28) | All Time Return 52.47 |
Forward Dividend Yield 0.0442 | Payout Ratio 0.6824 | Last Split Factor 5:1 | Forward Dividend Rate 2.04 | Dividend Date 2023-06-23 |
1 | Innate Pharma S.A. Q4 2023 Earnings Call Transcript | 03/22/2024 |
2 | XORTX Announces New ClinicalAdvisory Board Member | 03/27/2024 |
3 | Mercks Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment | 04/03/2024 |
4 | Innate Pharma Files Its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | 04/05/2024 |
5 | STAT Pharmalittle Were reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more | 04/08/2024 |
6 | After years of just running, running, a crisis led to a lupus diagnosis. Now she connects others | 04/09/2024 |
7 | RBC maintains stock price target on Regeneron amid DOJ complaint | 04/11/2024 |
8 | Layoffs announced at 2 big Bay Area biotech firms | 04/12/2024 |
9 | Regeneron commits 500M to new venture capital fund | 04/15/2024 |
| Begin Period Cash Flow | 12.7 B |
Sanofi |
Sanofi ADR Relative Risk vs. Return Landscape
If you would invest 5,083 in Sanofi ADR on January 20, 2024 and sell it today you would lose (544.00) from holding Sanofi ADR or give up 10.7% of portfolio value over 90 days. Sanofi ADR is generating negative expected returns assuming volatility of 1.0552% on return distribution over 90 days investment horizon. In other words, 9% of stocks are less volatile than Sanofi, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Sanofi ADR Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sanofi ADR's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sanofi ADR, and traders can use it to determine the average amount a Sanofi ADR's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1649
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNY |
Estimated Market Risk
| 1.06 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sanofi ADR is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sanofi ADR by adding Sanofi ADR to a well-diversified portfolio.
Sanofi ADR Fundamentals Growth
Sanofi Stock prices reflect investors' perceptions of the future prospects and financial health of Sanofi ADR, and Sanofi ADR fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sanofi Stock performance.
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 67.6 B | ||||
| Shares Outstanding | 2.5 B | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 2.52 X | ||||
| Revenue | 43.07 B | ||||
| Gross Profit | 31.7 B | ||||
| EBITDA | 12.96 B | ||||
| Net Income | 5.4 B | ||||
| Cash And Equivalents | 6.9 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 18.42 B | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | 59.17 X | ||||
| Cash Flow From Operations | 10.26 B | ||||
| Earnings Per Share | 2.28 X | ||||
| Market Capitalization | 113.46 B | ||||
| Total Asset | 126.46 B | ||||
| Retained Earnings | 67.5 B | ||||
| Working Capital | 6.46 B | ||||
| Current Asset | 24.93 B | ||||
| Current Liabilities | 16.82 B | ||||
About Sanofi ADR Performance
To evaluate Sanofi ADR Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Sanofi ADR generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Sanofi Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Sanofi ADR market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Sanofi's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 212.89 | 310.47 | |
| Return On Tangible Assets | 0.10 | 0.14 | |
| Return On Capital Employed | 0.09 | 0.17 | |
| Return On Assets | 0.04 | 0.08 | |
| Return On Equity | 0.07 | 0.13 |
Things to note about Sanofi ADR performance evaluation
Checking the ongoing alerts about Sanofi ADR for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sanofi ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sanofi ADR generated a negative expected return over the last 90 days | |
| Sanofi ADR has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: Regeneron commits 500M to new venture capital fund |
- Analyzing Sanofi ADR's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sanofi ADR's stock is overvalued or undervalued compared to its peers.
- Examining Sanofi ADR's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sanofi ADR's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sanofi ADR's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sanofi ADR's stock. These opinions can provide insight into Sanofi ADR's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.217 | Dividend Share 3.76 | Earnings Share 2.28 | Revenue Per Share 18.388 | Quarterly Revenue Growth 0.029 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.